NREP
NEW REPRESENTATIVE AT IB RECEIVED
06/18/2026
Back to search
Official data from USPTO
INVOX
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: US
Quick snapshot
INVOX
ST13
US500000079347617Class
5, 10, 36, 42, 45
Filing
79347617
Registration
7333791
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
33
Latest update
06/19/2026
Classification
Registered
Trademark type
Word
Nice classes
5, 10, 36, 42, 45
Filing date
05/26/2022
Registration date
03/26/2024
Expiration date
-
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Complete case details
Structured fields from the responsible authority and the official record.
Status date
03/26/2024
Last transaction
06/19/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
4
Owner type
99
Owner location
GB
Examiner
BERNS, LEE ANNE
Law office
M90
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
invoX Pharma Limited
Representatives
Catherine J. Holland Knobbe, Martens, Olson & Bear, LLP
Technical classification
Nice Classes
Class 5Class 10Class 36Class 42Class 45
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceuticals for use in oncologycardio-respiratoryhaematology and immunitypaediatric and regenerative medicine; Pharmaceutical preparations and substances for oncologycardio-respiratoryhaematology and immunitypaediatric and regenerative medicine and for the prevention and treatment of inflammation and infectious diseases; chemical preparations for pharmaceutical purposesfor use in oncologycardio-respiratoryhaematology and immunitypaediatric and regenerative medicine and for the treatment of inflammation and infectious diseases; chemical reagents for medical use; biotechnological preparations for medical use for use in oncologycardio-respiratoryhaematology and immunitypaediatric and regenerative medicine and for the treatment of inflammation and infectious diseases; biological adjuvants for medical purposes; biochemical preparations for medical use for use in oncologycardio-respiratoryhaematology and immunitypaediatric and regenerative medicine and for the treatment of inflammation and infectious diseases; preparations for deodorizing air; medicated deodorants for health and medical purposes; oils for medical purposes; air purifying preparationspharmaceutical preparations for inhalers; none of the aforesaid goods being disinfectants or sanitary preparationsnot being adapted for use as disinfectant or sanitisers; none of the aforesaid being goods for use in diagnostics or for use in the examinationprocessingtransportation or testing of veterinary or medical samples
Class 10
Surgical instruments and apparatusmedical devicesinhalation devices in the field of drug delivery systemsexcluding medical and veterinary sample containersprocessing and analysis machines and test kits and personal protective equipment (PPE); inhalers for medical and pharmaceutical purposes; none of the aforesaid being goods for use in the examinationprocessingtransportation or testing of veterinary or medical samples or for use in diagnostics or in laboratory automation for diagnostic purposessample handling or sample preparation enabling and/or supporting medicalpatient and veterinary data testingprocessing and/or analysis
Class 36
Financing and equity investment services in the fields of pharmaceuticalsbiotechnology life sciences; capital financing services in the fields of pharmaceuticalsbiotechnologylife sciences; making direct and indirect investmentsnamely providing venture capitalprivate equity and investment funding for the development and commercialization of products and management of product portfolios in the fields of pharmaceuticalsbiotechnologylife sciences; investment servicesasset and investment acquisitiondevelopment services; none of the aforesaid services being in relation to the examinationprocessingtransportation or testing services relating to veterinary or medical samples; none of the aforesaid services being in relation to diagnostic applications by means of medical samples or in the field of laboratory automation for diagnostic purposes by means of medical samplesspecimen handling or sample preparation or being in the field of software and IT services for enabling and/or supporting medicalpatient and veterinary sample data testingprocessing and/or analysis
Class 42
Pharmaceutical research and development in the field of biotechnologymedical devices in the field of drug delivery systems; scientific research for clinicalmedical and pharmaceutical purposes in the field of biotechnologymedical devices for drug delivery systems and life sciences; scientific research and development in the field of biotechnology medical deviceslife sciences and healthcare technology; pharmaceutical products development and medical device product development in the field of biotechnologymedical devices for drug delivery systems and life sciences; none of the aforesaid being in relation to the examinationprocessingtransportation or testing services relating to veterinary; none of the aforesaid services being in relation to diagnostic applications by means of medical samples or in the field of laboratory automation for diagnostic purposes by means of medical samplesspecimen handling or sample preparation or being in the field of software and IT services for enabling and/or supporting medicalpatient and veterinary sample data testingprocessing and/or analysis
Class 45
Licensing of intellectual property rights; licensing of intellectual property in the field of pharmaceuticalbiotechnologylife sciences; none of the aforesaid being in relation to the examinationprocessingtransportation or testing services relating to veterinary or medical samples; none of the aforesaid services being in relation to diagnostic applications by means of medical samples or in the field of laboratory automation for diagnostic purposes by means of medical samplesspecimen handling or sample preparation or being in the field of software and IT services for enabling and/or supporting medicalpatient and veterinary sample data testingprocessing and/or analysis
Publications
History of USPTO decisions and trademark events.
33 publications found
NREP
NEW REPRESENTATIVE AT IB RECEIVED
04/23/2026
LIMG
LIMITATION OF GOODS RECEIVED FROM IB
05/30/2025
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
11/23/2024
FICS
FINAL DISPOSITION NOTICE SENT TO IB
11/05/2024
FIMP
FINAL DISPOSITION PROCESSED
10/07/2024
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
06/27/2024
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
03/26/2024
R.PR
REGISTERED-PRINCIPAL REGISTER
03/26/2024
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
02/13/2024
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
01/24/2024
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
01/24/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
01/09/2024
PUBO
PUBLISHED FOR OPPOSITION
01/09/2024
GPNX
NOTIFICATION PROCESSED BY IB
01/08/2024
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
12/20/2023
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
12/20/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
12/20/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
12/05/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
11/07/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
11/06/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
11/06/2023
LIME
LIMITATION FROM THE IB - REQUEST EXAM REVIEW
10/24/2023
LIMG
LIMITATION OF GOODS RECEIVED FROM IB
07/30/2023
RFNT
REFUSAL PROCESSED BY IB
05/24/2023
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
05/04/2023
RFRR
REFUSAL PROCESSED BY MPU
05/04/2023
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
03/16/2023
CNRT
NON-FINAL ACTION WRITTEN
03/15/2023
DOCK
ASSIGNED TO EXAMINER
03/14/2023
MAFR
APPLICATION FILING RECEIPT MAILED
08/23/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
08/19/2022
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
08/18/2022
Continuous trademark protection
Get notified about every new filing that threatens INVOX or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.